<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485030</url>
  </required_header>
  <id_info>
    <org_study_id>20070044</org_study_id>
    <nct_id>NCT00485030</nct_id>
  </id_info>
  <brief_title>Diffuse Type In-Stent Restenosis After Drug-Eluting Stent</brief_title>
  <acronym>DES-ISR</acronym>
  <official_title>Comparison Between Drug-Eluting Stents for the Treatment of the Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation: Sirolimus-Eluting vs. Paclitaxel-Eluting Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting
      stent restenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite a significant reduction of angiographic restenosis and the need for repeat
      revascularization after introduction of DES, post-DES restenosis still occur and the
      treatment for DES failure is challenging. However, there have been little data for
      therapeutic strategy for post-DES restenosis, especially diffuse type ISR. Therefore, we need
      the well-designed randomized trial to achieve the best therapeutic option for the treatment
      of diffuse type post-DES restenosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binary in-segment angiographic restenosis</measure>
    <time_frame>at 9 months angiographic follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The composite of death, myocardial infarction, and target-vessel revascularization</measure>
    <time_frame>in-hospital, 1 month, and 9 months after index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>in-hospital, 1 month, and 9 months after index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss</measure>
    <time_frame>at 8 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success defined as achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion</measure>
    <time_frame>during the hospital stay</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sirolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience-V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>everolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher</intervention_name>
    <description>sirolimus-eluting stent</description>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_label>Xience-V</arm_group_label>
    <other_name>sirolimus-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience-V</intervention_name>
    <description>everolimus-eluting stent</description>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_label>Xience-V</arm_group_label>
    <other_name>everolimus-eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be at least 18 years of age.

          2. Restenosis after drug-eluting stents (&gt;50% by visual estimate)

          3. Lesion length â‰¥ 10 mm (diffuse type ISR)

          4. Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina
             pectoris Braunwald class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patients with
             atypical chest pain or without symptoms but having documented myocardial ischemia,
             amenable to stent-assisted percutaneous coronary intervention

          5. The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          1. The patient has a known hypersensitivity or contraindication to any of the following
             medications:

               -  Heparin

               -  Aspirin

               -  Both Clopidogrel and TIclopidine

               -  Sirolimus eluting stent

               -  Stainless steel and/or

               -  Contrast media (patients with documented sensitivity to contrast which can be
                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be
                  enrolled. Patients with true anaphylaxis to prior contrast media, however, should
                  not be enrolled).

          2. Systemic (intravenous) Sirolimus use within 12 months.

          3. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study.

          4. History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), or will refuse blood transfusions.

          5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery
             within 2 months.

          6. Current known current platelet count &lt;100,000 cells/mm3 or Hgb &lt;10 g/dL.

          7. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).

          8. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.

          9. Patients with EF&lt;30%.

         10. Acute MI patients within symptom onset &lt; 12 hours needing primary angioplasty

         11. Creatinine level 3.0mg/dL or dependence on dialysis.

         12. Severe hepatic dysfunction (AST and ALT 3 times upper normal reference values).

         13. Patients with left main stem stenosis and left main in-stent restenosis created by
             DES(&gt;50% by visual estimate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choeng Ju St.Mary's Hospital</name>
      <address>
        <city>Choeng Ju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>GangNeung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DongGuk University Gyongju Hospital</name>
      <address>
        <city>Gyongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwangju Christian Hospital</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital,</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangang Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungsang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2007</study_first_submitted>
  <study_first_submitted_qc>June 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2007</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>stent</keyword>
  <keyword>angioplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

